NCT06187506 2024-07-12Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder CancerFudan UniversityPhase 2 Recruiting20 enrolled
NCT05957757 2023-08-31RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 ExpressionRenJi HospitalPhase 2 Recruiting20 enrolled